This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
account_circleSign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Indications

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The principal use is in renal failure; priority indicators include:

  • transfusion dependency
  • angina - heart failure aggravated by anaemia
  • haemoglobin concentrations less than 8
  • livelihood threatened by anaemia
  • prevention of sensitisation to transplantation antigens

Other uses include:

  • patients anaemic due to malignant disease - improves anaemia, but quality of life probably not increased
    • there are concerns about using erythopoietin in patients with cancer:
      • study evidence revealed that erythropoiesis-stimulating agent administration to patients with cancer is associated with increased risks of venous thromboembolism (VTE) and mortality (1)

  • rheumatoid arthritis:
    • corrects anaemia
    • results in clinical improvement

  • Jehovah's witnesses:
    • useful following major surgery

  • haematologic disorders:
    • safe and effective in lymphoproliferative disorders
    • less good in haematopoietic disorders
    • iron deficiency is an important cause of failure to respond

Reference:

 

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.